FGFR2 and neoplasm: Aberrant activation of FGFR2 in GISTs, driven primarily by gene fusions (e.g., FGFR2::TACC2) and amplifications, triggers key oncogenic signaling pathways that promote tumor cell proliferation, survival, and resistance to TKIs [2,9].